A single treatment with a ready-to-use liquid botulinum toxin improved frown lines for most patients within a month, and some still rated themselves improved a year later. The findings come from a 12-month randomised, double-blind, placebo-controlled trial of relabotulinumtoxinA, published online on 10 November in Plastic and Reconstructive Surgery. This report is based on the published abstract.
RelabotulinumtoxinA, developed by Galderma and sold as Relfydess in several markets, differs from most aesthetic toxins because it arrives as a liquid. Most competitors are freeze-dried powders that clinics must reconstitute with saline before injecting. A liquid removes that step and the dosing variation it can bring.
What the trial did
Adults with moderate-to-severe glabellar (frown) lines received a single 50-unit dose or placebo, randomised 3:1. Patients and assessors were blinded. Follow-up lasted 12 months, longer than the 4–6 months of typical toxin registration trials.
The primary endpoint was how patients rated their own appearance at maximum frown, using the Global Aesthetic Improvement Scale (GAIS), one month after injection.
What it found
At one month, 92.9% of treated patients (92 of 99) rated themselves improved, against 9.1% on placebo (3 of 33; p<0.001).
Self-rated improvement persisted in 42.7% at nine months and 37.8% at 12 months.
Investigators used a stricter line-severity scale (GL-ILA). By that measure, at least one grade of improvement was seen in 57.4% at six months, 28.1% at nine months and 12.2% at 12 months.
Onset was fast: 39.8% of patients rated themselves improved within a day, and 43.9% met the investigator criterion.
Treatment-related adverse events occurred in 8.1% and were all mild.
Reading the durability claim carefully
The headline durability figures depend on which scale is used. Self-rated improvement held up better than investigator-rated improvement: at one year, nearly four in ten patients felt better, but only about one in eight still showed a measurable one-grade change.
Both views are clinically useful. Patients care how they feel about their appearance, and GAIS captures that. But GAIS is softer and more prone to expectation effects than a graded line scale. For practitioners setting expectations, the honest summary is: most patients see a strong effect for several months, and a minority keep some benefit up to a year.
The early-onset finding may matter more in daily practice. Two in five patients noticing a change within 24 hours is faster than most freeze-dried toxins are usually described, though this trial did not compare products head to head.
Why it matters
The trial lands while the product’s US status is unresolved. On 1 July 2026 Galderma said the US Food and Drug Administration had issued a Complete Response Letter, its second for the product. Galderma said the letter related to observations at a manufacturing-site inspection and to analytical-method optimisation. It said the safety and efficacy sections raised no deficiencies. No new US resubmission has been announced since.
For US clinicians, the study adds to the evidence that FDA reviewers already hold, but it does not change the reason for the delay. For clinicians in markets where the product is available, it supports a single standard dose and gives realistic numbers for consultations.
Limitations
One dose (50 U) was tested, so the results do not inform dose tailoring.
The placebo group was small (33 patients at month one).
There was no active comparator, so the trial cannot show the liquid lasts longer or works faster than other toxins.
The bottom line
This is solid, controlled evidence that one dose of liquid relabotulinumtoxinA works quickly and reliably for frown lines over the first months. It is weaker evidence for a “one-year toxin”. Patients should expect to need retreatment within the usual interval, with some longer-lasting responders.
The two durability scales answer different questions. A patient may still feel that the appearance has improved even after a clinician no longer records a clear grade change. Neither result is meaningless. However, presenting only the higher self-rating at one year could mislead readers about the persistence of a visible clinical effect.
The trial used a single dose of a liquid product and placebo, not another marketed toxin. Consequently, it cannot prove faster onset or longer duration than competing products. The report also does not establish that every person can wait a year between treatments.
The regulatory context needs equal care. A complete response letter from the US FDA is not a product approval. Galderma said in July that its US application faced manufacturing and analytical issues, rather than safety or efficacy deficiencies. That is the company’s account of the letter; the trial does not change US authorization status.
A useful consultation should separate early response, peak improvement, duration of visible line reduction and patient satisfaction. Those measures can diverge. Patients may also vary in muscle strength, baseline line depth and treatment expectations.
This is meaningful controlled research, yet the strongest evidence concerns the early months after one treatment. Longer follow-up helps define the tail of response; it does not guarantee year-long wrinkle control.
Original source
https://doi.org/10.1097/PRS.0000000000013599
Medical information disclaimer
This article is published by Aesthetics.news for general information and educational purposes only. It does not constitute medical advice, diagnosis or treatment, and should not replace a consultation with a qualified healthcare professional. Treatments and outcomes may vary from person to person. Readers should seek advice from an appropriately qualified professional before making decisions about their health or treatment. In a medical emergency, seek immediate medical assistance.
